Clotting and fibrinolytic disturbance during lung transplantation: Effect of low-dose aprotinin  by Gu, Y.J. et al.
CLOTTING AND FIBRINOLYTIC DISTURBANCE DURING LUNG TRANSPLANTATION: EFFECT OF 
LOW-DOSE APROTININ 
Y. J. Gu, MD, PhD 
J. de Haan, PhD 
U. P. M. Brenken, MD, PhD 
W. J. de Boer, MD 
Jm. Prop, MD, PhD 
W. van Oeveren, PhD 
Groningen Lung Transplant Group 
Patients undergoing lung transplantation are often confronted with a bleeding 
problem that may be due in part to the use of cardiopulmonary b pass and its 
activation of blood clotting and fibrinolysis. Objective: We performed a pro- 
spective study to determine whether and to what extent the clotting and 
fibrinolytic systems are being activated and whether low-dose aprotinin is 
effective in inhibiting blood activation during lung transplantation. Methods: 
Thirty lung transplantations performed on 29 patients were divided into a 
group with cardiopulmonary b pass alone (n = 12), a group with cardiopul- 
monary bypass and 2 × 106 KIU aprotinin administered at the beginning of 
bypass in the pump prime (n = 12), and a group without cardiopulmonary 
bypass (n = 6). Serial blood samples were taken from the recipient before 
anesthesia, seven times during the operation, and 4 and 24 hours thereafter. 
Results: Results show that in the group having cardiopulmonary b pass alone, 
the concentration of the clotting marker thrombin/antithrombin II I  complex 
increased significantly during the arly phase of the operation (p < 0.01) and 
remained high until the end of the operation. Levels of tissue-type plasminogen 
activator, a trigger of fibrinolysis released by injured endothelium, also 
increased sharply in the early phase of the operation in the cardiopulmonary 
bypass group (p < 0.01), followed by a significant increase in fibrin degrada- 
tion products (p < 0.01). In the aprotinin group, a significant reduction of 
thrombin/antithrombin Ill complex (p < 0.05), tissue-type plasminogen acti- 
vator (p < 0.05), and fibrin degradation products (p < 0.05) was observed in 
the early phase of the operation compared with levels in the bypass group, but 
these markers increased late during bypass associated with a significant drop 
(p < 0.05) of plasma protinin level monitored by plasmin inhibiting capacity. 
In the nonbypass group, concentrations of thrombin/antithrombin HI complex 
and tissue-type plasminogen activator also rose significantly (p < 0.05) in the 
early phase of the operation, but the levels were significantly lower than those 
of the bypass group (p < 0.05). Blood loss during the operation was 2521 - 550 
ml in the bypass group, 1991 -+ 408 ml in the aprotinin/bypass group, and 875 
- 248 ml in the nonbypass group. Conclusion: These results suggest hat 
clotting and fibrinolysis are activated uring lung transplantation, especially 
in patients undergoing cardiopulmonary bypass. Aprotinin in a low dose 
significantly reduced activation of clotting and fibrinolysis in the early phase of 
the operation but not during the late phase of lung transplantation. (J Thorac 
Cardiovasc Surg 1996;112:599-606) 
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p atients undergoing lung transplantation are of- 
ten confronted with excessive intraoperative 
bleeding followed by large amounts of transfused 
blood.l-3 To a large extent, this problem is attributed 
to the underlying lung diseases, which require ex- 
tensive surgical manipulation of the chest wall dur- 
ing the operation, e Furthermore, cardiopulmonary 
bypass (CPB) is frequently used during lung trans- 
plantation to support the recipient's hemodynamic 
stability.4, 5However, the use of CPB may aggravate 
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Table I. Patients demographic data (mean +_ 
standard deviation) 
CPB CPB/aprotinin Non-CPB 
Parameter (n = 12) (n = 12) (n = 6) 
Age (yr) 40 _+ 10 38 _+ 11 45 _+ 15 
Sex (M/F) 7/5 8/4 5/1 
Pulmonary vascular disease 3 4 - -  
Obstructive lung disease 5 4 2 
Restrictive lung disease 1 - -  3 
Infectious lung disease 3 4 1 
the bleeding problem as a result of adverse effects 
such as blood-material interaction, systemic hepa- 
rinization, and recirculation of wound blood that 
may disturb clotting and fibrinolysis in lung trans- 
plantation.6, 7 
Although the disturbance of clotting and fibrino- 
lysis during cardiac operations has been widely 
investigated, 8-1° little is known about its occurrence 
and prevention during lung transplantation. The 
antifibrinolytic agent aprotinin has been beneficial 
in reducing bleeding and blood transfusion in pa- 
tients undergoing cardiac operations. TM 12 Similarly, 
a beneficial effect of aprotinin might be expected 
during lung transplantation if similar activation of 
clotting and fibrinolysis occurs as during cardiac 
operations. Therefore we performed a prospective 
study to determine whether and to what extent the 
clotting and fibrinolytic systems were activated ur- 
ing lung transplantation and whether use of aproti- 
nin in a single low-dose regimen, as during cardiac 
operations, was effective in inhibiting blood activa- 
tion for patients undergoing lung transplantation. 
Patients and methods 
After approval by the local ethical committee in the 
University Hospital Groningen and informed consent 
obtained from patients, 30 lung transplantation opera- 
tions performed on 29 patients were allocated into the 
following three study groups: group 1, with CPB (n = 12); 
group 2, with CPB and 2 × 106 KIU aprotinin adminis- 
tered at the beginning of CPB in the pump prime (n = 
12); and group 3, without CPB (n = 6). Four unilateral 
and eight bilateral ung transplantations were performed 
in the CPB group; five unilateral and seven bilateral 
transplantations in the aprotinin/CPB group, and four 
unilateral and two bilateral transplantations in the non- 
CPB group. Patients' demographic data, as well as the 
preoperative lung disease in each group, are listed in 
Table I. 
The donor lungs were preserved by pulmonary artery 
flush perfusion with a modified Euro-Collins solution of 
10 ° C containing prostacyclin. After perfusion the lungs 
were separated from the heart and stored on sterile ice 
during transportation. Recipient anesthesia was per- 
Table II. Duration o f  CPB, blood loss, and 
transfusion (mean +_ standard deviation) 
CPB CPB/aprotinin Non-CPB 
Parameter (n = 12) (n - 12) (n = 6) 
CPB time (min) 224 _+ 60 275 _+ 68 - -  
Total heparin (mg) 321 _+ 102 336 _+ 60 - -  
Protamine (mg) 191 _+ 44 177 _+ 24 - -  
Blood loss (ml) 2521 _+ 1740 1991 _+ 1353 875 + 607 
RBC transfusion (unit) 6.5 _+ 2.9 7.4 _+ 3.1 1.0 + 1.2" 
CPB, Cardiopulmonary b pass; RBC, red blood cell concentrate. 
*p < 0.01 in comparison with the other two groups. 
formed with a high-dose opioid-midazolam infusion tech- 
nique and oxygen in air ventilation to normocapnic levels. 
Lung implantation was performed for unilateral and 
bilateral sequential procedures according to the surgical 
technique described by Cooper 13 and Pasque and associ- 
ates. TM 
CPB. CPB was used for recipients from both the CPB 
and the aprotinin/CPB groups. The extracorporeal circuit 
consisted of roller pumps and a silicone sheet membrane 
oxygenator (SciMed Life Systems, Inc., Minneapolis, 
Minn.) or a microporous polypropylene membrane oxy- 
genator (CML Excel; Cobe Laboratories, Inc., Lakewood, 
Colo.). The circuit was primed with human albumin and 
Ringer's lactate solution containing 1500 IU heparin. 
Before the start of CPB, systemic heparinization was 
achieved by intravenous administration of bovine lung 
heparin (300 IU/kg). During CPB, anticoagulation was 
maintained by additional heparin (100 IU/kg per hour) 
and monitored by the celite-activated clotting time 
(Hemochron 800, International Technidyne Corp., Edi- 
son, N.J.). Protamine hydrochloride was administered 
after CPB at a ratio of 1:1 to the loading dose of heparin 
after completion of CPB. 
Laboratory measurements. For the different assays of 
clotting, fibrinolysis, and aprotinin activity, blood samples 
were taken from the indwelling radial artery catheter 
of the recipients at nine time points: after induction of 
anesthesia before the operation (T1), after the start of 
CPB but before reperfusion of the first lung (T2), 5 
minutes (T3) and 30 minutes (T4) after reperfusion of the 
first lung, 5 minutes (T5) and 30 minutes (T6) after 
reperfusion of the second lung if there was a bilateral 
procedure, at the end of the operation (T7), and 4 hours 
(T8) and 24 hours (T9) after the end of the operation. 
Samples were anticoagulated either with 3.06% sodium 
citrate solution or with citrate solution containing a 100 
KIU/ml concentration of aprotinin in a blood/medium 
ratio of 9:1. Plasma was obtained by centrifugation of 
whole blood at 1000 g and stored at -80 ° C for further 
determination. 
Activation of clotting was indicated by the concentra- 
tion of the thrombin-antithrombin III (TAT) complex 
measured in citrate-antieoagulated plasma by enzyme- 
linked immunosorbent assay (ELISA, Behring, Marburg, 
Germany). Activation of fibrinolysis was indicated by 
fibrin degradation products (FbDP) in the citrate-aproti- 
nin plasma by ELISA (Organon Teknika, Turnhout, Bel- 
gium). Tissue-type plasminogen activator (t-PA) concen- 
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Fig. 1. Formation of TAT complex during lung transplantation i  patients with CPB, with CPB and 
aprotinin (CPB+aprotinin), and without CPB (non-CPB). Significant higher TAT was found in the CPB 
group than the CPB+aprotinin and the non-CPB groups (*p < 0.05, comparison between groups; 
within-group difference, see text in Results; sample time T1 to T9, see text in Methods). 
trations was determined in citrate-anticoagulated plasma 
by ELISA (Kabi Diagnostica, Stockholm, Sweden). Apro- 
tinin activity was estimated by plasmin inhibiting capacity 
in citrated plasma samples. In brief, plasma samples were 
added to an excess of plasmin in buffer. Next, the residual 
turnover of a plasmin-specific chromogenic substrate (S- 
2403, Chromogenix A.B., M61ndal, Sweden)was deter- 
mined and measured as an increased optical density at 405 
nm in a spectrophotometer (model 3550-UV, Bio-Rad 
Laboratories, Hercules, Calif.). 
Clinical data. Total heparin and protamine doses used 
during the operation were calculated from the anesthetic 
records. Blood loss during the whole period of the oper- 
ation was recorded according to the net weight of gauzes 
and the volume of the wound drainage system. Transfu- 
sion of red blood cell concentrates was decided on the 
basis of hemoglobin level during the operation. 
Statistics. Data are expressed as mean value _+ the 
standard error of the mean except when stated otherwise. 
All the values of laboratory tests except the plasmin 
inhibiting capacity were corrected for hemodilution by the 
baseline hematocrit value before the operation (sample 
value × baseline hematocrit/sample hematocrit). After 
evaluation of data distribution by the Kolmogorov-Smir- 
nov test, either one-way analysis of variance or the 
Kruskal-Wallis test was applied for comparing differences 
among the three groups. If a significance was observed, 
either Student's t test or the Mann-Whitney test was 
performed to determine the significance between each 
two groups. For the time-dependent difference within a 
group, the paired t test was applied. A p value less than 
0.05 was considered as statistically significant. 
Resu l ts  
C l in ica l  data.  The mean duration of CPB was 
224 minutes (107 to 300 minutes) in the CPB group 
and 275 minutes (213 to 414 minutes) in the apro- 
tinin/CPB group. Blood loss during the operation 
was 2521 + 550 ml in the CPB group, 1991 _ 408 ml 
in the aprotinin/CPB group, and 875 + 248 ml in the 
non-CPB group. No statistically significant differ- 
ence was observed between the groups regarding the 
duration of CPB and blood loss. There was also no 
significant difference between the CPB and the 
aprotinin/CPB groups in transfusion of red blood 
cell concentrates and fresh frozen plasma. The 
volume of red cell concentrates transfused was 
significantly lower in the non-CPB group than in the 
other two groups (p < 0.01). Total amount of 
heparin and protamine administered uring the 
operation did not differ between the CPB and 
CPB/aprotinin groups (Table II). 
TAT complex. The level of TAT complex, an 
indicator of clotting activation, increased signifi- 
cantly during the early phase of the operation in the 
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Fig. 2. t-PA release during lung transplantation i patients with CPB, with CPB and aprotinin 
(CPB+aprotinin), and without CPB (non-CPB). (*p < 0.05, CPB group versus CPB+aprotinin and 
non-CPB groups). 
CPB group in comparison with its baseline concen- 
tration (from 12 _+ 2 ng/ml to 213 _+ 28 ng/ml, p < 
0.01). High levels of TAT complex were continu- 
ously found in plasma during the late phase of the 
operation but declined sharply 4 hours after the 
operation and returned to baseline level within 24 
hours. The increase of TAT complex was signifi- 
cantly less in the aprotinin/CPB group than in the 
CPB group at the initiation of CPB (p < 0.05, Fig. 
1), but the concentration rose progressively late 
during the operation and returned to the baseline 
level in a pattern similar to that of the CPB group. 
In the non-CPB group, plasma concentration of 
TAT also rose during the operation, but it was 
significantly less than the concentration i the CPB 
group (p < 0.05, T2 to T4). 
t-PA. The concentration of t-PA, a trigger of 
fibrinolysis released by injured endothelium, in- 
creased sharply in the early phase of the operation 
in the CPB group (from 13.6 +- 5.7 ng/ml to 44.9 _+ 
6.9 ng/ml, p < 0.01), followed by a second peak 
during the late phase of the operation. The t-PA 
concentration i plasma dropped sharply after the 
end of the operation and remained slightly elevated 
for 24 hours. In the aprotinin/CPB group, signifi- 
cantly less t-PA was found in circulation than in the 
CPB group early during CPB (p < 0.05, Fig. 2), but 
it increased later during CPB; thus no statistically 
significant difference existed between the two 
groups. In the non-CPB group, t-PA also increased 
significantly during the early period of operation (T2 
to T4) in comparison with the baseline concentra- 
tion (p < 0.05), but the level was significantly lower 
than that in the CPB group (p < 0.05). 
FbDP. The concentration of FbDP, an indicator 
of fibrinolysis, increased significantly during the 
operation in the CPB group (T4 and T7 in compar- 
ison with baseline, p < 0.01). However, the plasma 
concentration was significantly lower in the aproti- 
nin/CPB group at T4 (57.0 _+ 6.4/,g/ml vs 18.2 _+ 6.5 
/xg/ml, p < 0.05, Fig. 3). There was no increase of 
FbDP in the non-CPB group. Within 24 hours FbDP 
returned to the baseline level in all groups. 
Plasmin inhibiting capacity. Plasmin inhibiting 
capacity reflecting aprotinin activity increased im- 
mediately after the initiation of CPB in the aproti- 
nin/CPB group and remained high during the early 
phase of the operation. Late during the operation 
the inhibiting capacity dropped significantly on 
transplantation f the second lung (p < 0.05, Fig. 4). 
In contrast o the mechanism in the aprotinin/CPB 
group, the plasmin inhibiting capacity dropped in 
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Fig. 3. FbDP production during lung transplantation i patients with CPB, with CPB and aprotinin 
(CPB+aprotinin), and without CPB (non-CPB). (*p < 0.05, comparison between the CPB and the 
CPB + aprotinin groups). 
the CPB group during the operation (data not 
corrected for hemodilution). 
Discussion 
Clotting appeared vigorously activated during 
lung transplantation a d increased synergistically by 
CPB, whereas excessive fibrinolysis appeared to be 
limited to patients requiring use of CPB. In lung 
transplantation, the concentrations of TAT com- 
plex, t-PA, and FbDP were two, three, and ten times 
higher, respectively, than those in cardiac opera- 
tions. Use of CPB is known to extensively activate 
clotting and fibrinolysis during cardiac operations, 
contributing to an acquired coagulopathy and in- 
creased bleeding tendency during and after the 
operations. 8q° The activation and subsequent con- 
sumption of clotting factors may result in weakness 
of clot formation, whereas the overstimulation of 
fibrinolysis may further promote clot lysis. Similarly, 
widespread activation of clotting and fibrinolysis 
during lung transplantation may have led to in- 
creased bleeding. 
Previously, we 15 have reported that activation of 
clotting during lung transplantation, asindicated by 
the formation of TAT complex, was about twice as 
high as observed uring cardiac operations. In the 
current study, we further observed that not only the 
extent but also the pattern of clotting activation 
during lung transplantation was different from what 
has been observed during cardiac operations. In 
cardiac operations, increased TAT complex was 
found only in the late phase of CPB, when suction of 
the wound blood intensified. 7' 16 In lung transplan- 
tation, however, TAT complex had already in- 
creased significantly in the early phase of the oper- 
ation. The early activation of the clotting system 
seen in patients undergoing lung transplantation 
could probably be explained by a larger wound area 
in these patients to allow surgical separation of 
pleural adhesion. Such a surgical trauma-induced 
clotting disturbance identified by the increase of 
TAT complex was also evident in patients undergo- 
ing lung transplantation without CPB 15 and other 
patients having general thoracic operations. 17It has 
been stated recently that even during cardiac oper- 
ations the major trigger of clotting activation was 
not the contact of blood with the foreign material 
(intrinsic clotting pathway), but the release of tissue 
factor (extrinsic clotting pathway) resulting from 
surgical trauma to blood vessels. 18 Moreover, we 19 
have recently demonstrated that the retainment of 
thoracic wound blood during cardiac operations 
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Fig. 4. Plasmin inhibiting capacity representing in part the functional aprotinin level during lung 
transplantation in patients with CPB or with CPB and aprotinin (CPB+aprotinin). It remained high in the 
aprotinin group during the early period of lung transplantation but dropped significantly afterward uring 
the late period of the operation (*p < 0.05, within-group comparison). 
resulted in significant reduction of TAT complex 
formation and postoperative blood loss. 19 These 
reports support the consensus that blood-material 
contact in the heart-lung machine is not the mere 
cause leading to activation of the clotting cascade in 
lung transplantation. 
Similar to the activation of clotting, fibrinolysis 
was also found to be activated both "intrinsically" 
and "extrinsically" during lung transplantation. The 
foreign material surface in the CPB circuit is known 
to activate fibrinolysis intrinsically through the con- 
tact activation mechanism. 2°' 21 During lung trans- 
plantation, however, activation of fibrinolysis may 
also be triggered extrinsically by t-PA released from 
stimulated or injured endothelial cells. In the 
present study, a finding completely in contrast o 
that seen in cardiac operations was that t-PA in- 
creased sharply during the early phase of CPB (see 
Fig. 2), followed by a significant increase of FbDP 
(see Fig. 3). It is known that t-PA is the most potent 
activator of plasminogen that initiates fibrinolysis. 9
Furthermore, t-PA together with soluble fibrin may 
synergistically cause platelet dysfunction, resulting 
in impairment of hemostasis. 1° 
Aprotinin, a nonspecific proteinase inhibitor, was 
expected to be beneficial for patients undergoing 
lung transplantation, because it has been demon- 
strated to reduce nonsurgical bleeding in patients 
undergoing cardiac operations with CPB. TM 12 Dur- 
ing cardiac operations, a low-dose regimen (2 × 106 
KIU) administered in the pump priming solution 
has been as effective as the high-dose infusion (6 × 
106 KIU) in terms of inhibiting the CPB-induced 
blood activation and blood saving. 22'23 Further- 
more, low-dose aprotinin treatment is considered 
less likely to induce postoperative r nal damage. 24 
As observed in this study of patients having lung 
transplantation, fibrinolysis was sufficiently inhibited 
during the initial phase of the operation by a low 
dose of aprotinin as identified by increased plasmin 
inhibiting capacity (see Fig. 4). However, late during 
the operation the inhibiting effect of aprotinin was 
reduced, with a significant drop of plasmin inhibit- 
ing capacity in plasma. Because in this study patients 
receiving aprotinin had received no less heparin 
than patients not receiving aprotinin, it is less likely 
that the reduction of plasmin inhibiting capacity at 
the late period of operation was due to a reduced 
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anticoagulation. It thus seems that the low-dose 
regimen of aprotinin administered in the pump 
priming solution for patients having lung transplan- 
tation inhibits fibrinolysis only during the early 
phase but not during the whole period of the 
operation because of massive activation of fibrino- 
lysis. Therefore a maintaining dose at least during 
the late period of lung transplantation must be 
considered in case the patient needs to receive 
aprotinin. 
An  obvious limitation of this study was that these 
patients were not randomized to receive aprotinin. 
From the clinical point of view, patients in the 
aprotinin-treated group are those who were consid- 
ered to be at high risk for bleeding and postopera- 
tive morbidity. However, no greater blood activation 
and blood loss was observed in these patients than in 
those who underwent CPB without receiving apro- 
tinin, which suggests that patients at high risk for 
bleeding benefited from aprotinin administration. 
This observation is in agreement with results of a 
recent nonrandomized retrospective study by Ja- 
quiss, Huddleston, and Spray, 25 which indicated that 
aprotinin reduced intraoperative blood loss and 
transfusion requirements in a group of pediatric 
patients undergoing lung transplantation proce- 
dures. In addition, the beneficial effect of aprotinin 
was also reported recently by Kesten and cowork- 
ers 26 in sequential single-lung transplant patients 
undergoing CPB. 
We conclude from this study that clotting and 
fibrinolysis are activated during lung transplanta- 
tion, particularly in the early phase of  the opera- 
tion. The observed disturbance of clotting and 
fibrinolysis during lung transplantat ion is caused 
by a combined effect of  surgical t rauma and CPB. 
Aprot in in  administrat ion i  a dose of 2 × 106 K IU  
in the pump pr ime significantly reduced the dis- 
turbance of clotting and fibrinolysis during the 
early phase of  lung transplantat ion but did not last 
for the whole per iod of  the operation. Further  
investigation may focus on a dose-response rela- 
t ionship between aprotinin and the suppression of  
clotting and fibrinolytic activation in patients un- 
dergoing lung transplantation. 
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